-
Robert J Adams, Greg Albers,
Mark J Alberts,
Oscar Benavente,
Karen Furie,
Larry B Goldstein,
Philip Gorelick,
Jonathan Halperin,
Robert Harbaugh,
S Claiborne Johnston,
Irene Katzan,
Margaret Kelly-Hayes,
Edgar J Kenton,
Michael Marks,
Ralph L Sacco,
Lee H Schwamm
Stroke 06/2008; 39(5):1647-52. · 5.73 Impact Factor
-
Stroke 10/2006; · 5.73 Impact Factor
-
Ralph L Sacco,
Robert Adams, Greg Albers,
Mark J Alberts,
Oscar Benavente,
Karen Furie,
Larry B Goldstein,
Philip Gorelick,
Jonathan Halperin,
Robert Harbaugh,
S Claiborne Johnston,
Irene Katzan,
Margaret Kelly-Hayes,
Edgar J Kenton,
Michael Marks,
Lee H Schwamm,
Thomas Tomsick
[show abstract]
[hide abstract]
ABSTRACT: The aim of this new statement is to provide comprehensive and timely evidence-based recommendations on the prevention of ischemic stroke among survivors of ischemic stroke or transient ischemic attack. Evidence-based recommendations are included for the control of risk factors, interventional approaches for atherosclerotic disease, antithrombotic treatments for cardioembolism, and the use of antiplatelet agents for noncardioembolic stroke. Further recommendations are provided for the prevention of recurrent stroke in a variety of other specific circumstances, including arterial dissections; patent foramen ovale; hyperhomocysteinemia; hypercoagulable states; sickle cell disease; cerebral venous sinus thrombosis; stroke among women, particularly with regard to pregnancy and the use of postmenopausal hormones; the use of anticoagulation after cerebral hemorrhage; and special approaches for the implementation of guidelines and their use in high-risk populations.
Circulation 04/2006; 113(10):e409-49. · 14.74 Impact Factor
-
Werner Hacke, Greg Albers,
Yasir Al-Rawi,
Julien Bogousslavsky,
Antonio Davalos,
Michael Eliasziw,
Michael Fischer,
Anthony Furlan,
Markku Kaste,
Kennedy R Lees,
Mariola Soehngen,
Steven Warach
[show abstract]
[hide abstract]
ABSTRACT: Most acute ischemic stroke patients arrive after the 3-hour time window for recombinant tissue plasminogen activator (rtPA) administration. The Desmoteplase In Acute Ischemic Stroke trial (DIAS) was a dose-finding randomized trial designed to evaluate the safety and efficacy of intravenous desmoteplase, a highly fibrin-specific and nonneurotoxic thrombolytic agent, administered within 3 to 9 hours of ischemic stroke onset in patients with perfusion/diffusion mismatch on MRI.
DIAS was a placebo-controlled, double-blind, randomized, dose-finding phase II trial. Patients with National Institute of Health Stroke Scale (NIHSS) scores of 4 to 20 and MRI evidence of perfusion/diffusion mismatch were eligible. Of 104 patients, the first 47 (referred to as Part 1) were randomized to fixed doses of desmoteplase (25 mg, 37.5 mg, or 50 mg) or placebo. Because of an excessive rate of symptomatic intracranial hemorrhage (sICH), lower weight-adjusted doses escalating through 62.5 microg/kg, 90 microg/kg, and 125 microg/kg were subsequently investigated in 57 patients (referred to as Part 2). The safety endpoint was the rate of sICH. Efficacy endpoints were the rate of reperfusion on MRI after 4 to 8 hours and clinical outcome as assessed by NIHSS, modified Rankin scale, and Barthel Index at 90 days.
Part 1 was terminated prematurely because of high rates of sICH with desmoteplase (26.7%). In Part 2, the sICH rate was 2.2%. No sICH occurred with placebo in either part. Reperfusion rates up to 71.4% (P=0.0012) were observed with desmoteplase (125 microg/kg) compared with 19.2% with placebo. Favorable 90-day clinical outcome was found in 22.2% of placebo-treated patients and between 13.3% (62.5 microg/kg; P=0.757) and 60.0% (125 microg/kg; P=0.0090) of desmoteplase-treated patients. Early reperfusion correlated favorably with clinical outcome (P=0.0028). Favorable outcome occurred in 52.5% of patients experiencing reperfusion versus 24.6% of patients without reperfusion.
Intravenous desmoteplase administered 3 to 9 hours after acute ischemic stroke in patients selected with perfusion/diffusion mismatch is associated with a higher rate of reperfusion and better clinical outcome compared with placebo. The sICH rate with desmoteplase was low, using doses up to 125 microg/kg.
Stroke 02/2005; 36(1):66-73. · 5.73 Impact Factor
